OCTS 2020 | Kisaco Research

OCTS

Revolutionizing patient outcomes in cancer therapies

Download agenda
Boston, USA
7-8 April, 2020

Revolutionizing patient outcomes in cancer therapies. Formerly the CAR-T Congress USA

Why Attend

Onco Cell Therapy Summit (OCTS), formerly the CAR-T Congress, is an event that brings industry together to share novel research, manufacturing techniques and regulatory best practice. Each session of OCTS 2020 is dedicated to translating your novel data assets & IP into commercially viable oncological therapies.

OCTS is a 4-track event and whilst bringing together the key decision makers for CAR-T therapies, this year’s event will have an added focus on the ground breaking science that is driving the surge of interest in harnessing alternative cell therapies in cancer treatments.

With 2 of our tracks comprised of research on CAR-T and alternative cell therapies, the other pillar in rolling out these therapies is increasing the affordability of the treatments. The other two tracks will delve into best practice in commercialization and manufacturing of immuno-oncological cell therapies.

Each day of the summit will conclude in plenary room panels that spin out into bespoke roundtable discussions to break down the key challenges in major topics to R&D, manufacturing and commercialization.

Cell Therapy Event Gallery

CAR-T image gallery

TESTIMONIALS

Feedback from past attendees

WHO WILL BE THERE

Network with industry experts from:

  • Big pharma and biotech
  • Cell Therapy Academics and clinicians 
  • Process standardisation - technology/services
  • Logistics companies - cell storage/transport
  • Service providers - CRO’s, Consultants, Government

Past attendees include:

Previous attendees

The Agenda

Following the third annual CAR-T Congress earlier this year, we recognized a need for more content, covering regulation, alternative cell therapies and commercialization. Introducing the Onco Cell Therapy Summit (OCTS), dedicated to translating the emerging novel data from leading academia and innovating biotechs into commercially viable therapies.

Join us to take a deep dive into the research on solid tumors and “off the shelf”
therapies that are defining the direction for oncological cell therapy development
pipelines. Each day of the congress will conclude in plenary room panels that spin out into bespoke roundtable discussions to break down the key challenges in major topics to R&D, manufacturing and commercialization.

New for this year

• 4 tracks focusing on: CAR-T R&D, Alternative Cell Therapies, Vein-to-Vein
Commercialization, Regulation and Safety;

• More networking across the industry, with a larger exhibition area the new OCTS APP to organize private one-to-one meetings.

We hope that you will join us at the end of day 1 as our infamous CAR-T Party returns.

OCTS Front page

Download Agenda

The Speakers

 

Carl June

Professor of Immunotherapy
University of Pennsyvania

Carl June

Professor of Immunotherapy
University of Pennsyvania

Carl June

Professor of Immunotherapy
University of Pennsyvania
 

Crystal Mackall

Director, Standford Center for Cancer Cell Therapy
Stanford University

Crystal Mackall

Director, Standford Center for Cancer Cell Therapy
Stanford University

Crystal Mackall

Director, Standford Center for Cancer Cell Therapy
Stanford University
 

Knut Niss

Chief Technology Officer
Mustang Bio

Dr. Niss has served as Chief Technology Officer since March 2018. Dr. Niss joined Mustang in March 2017 as Vice President of Operations, where he initiated and oversees the establishment of Mustang’s cell therapy manufacturing facility. Prior to Mustang, Dr. Niss was Cell Therapy Asset Leader at Biogen, where he oversaw CMC-related activities for gene-edited hematopoietic stem cell and lentiviral gene therapy programs for sickle cell disease and hemophilia, respectively. Earlier in his career, Dr.

Knut Niss

Chief Technology Officer
Mustang Bio

Knut Niss

Chief Technology Officer
Mustang Bio

Dr. Niss has served as Chief Technology Officer since March 2018. Dr. Niss joined Mustang in March 2017 as Vice President of Operations, where he initiated and oversees the establishment of Mustang’s cell therapy manufacturing facility. Prior to Mustang, Dr. Niss was Cell Therapy Asset Leader at Biogen, where he oversaw CMC-related activities for gene-edited hematopoietic stem cell and lentiviral gene therapy programs for sickle cell disease and hemophilia, respectively. Earlier in his career, Dr. Niss was Senior Technical Project Leader at Novartis’ cell therapy manufacturing facility in Morris Plains, New Jersey, where he directed the transfer and implementation of the CTL019 process from Penn to Novartis. He also served as Senior R&D Program Manager at EMD Millipore, where he established processes for the large-scale expansion of adult and pluripotent stem cells. Dr. Niss began his career in senior research positions in Pfizer’s Regenerative Medicine and Immunology groups. He holds a Ph.D. in molecular biology from Humboldt University of Berlin, and an M.S. in microbiology from the University of Göttingen in Germany. Dr. Niss completed his postdoctoral research at Boston Children’s Hospital and the Dana-Farber Cancer Institute.

 

 

Peter Emtage

Cell Design Labs

Dr. Emtage currently serves as Chief Scientific Officer at Cell Design Labs, Inc. (CDL). Prior to joining CDL, he was Vice President of Synthetic Immunology at Intrexon Corporation and was Vice President of Immune Mediated Therapy in the Oncology Innovative Medicines group at Medimmune. At Medimmune, Dr. Emtage designed and implemented a comprehensive immune therapy cancer strategy. He has over sixteen years of biologics development experience in the fields of oncology, autoimmunity, infectious diseases, and inflammation. Dr. Emtage holds a B.S. and M.S.

Peter Emtage

Cell Design Labs

Peter Emtage

Cell Design Labs

Dr. Emtage currently serves as Chief Scientific Officer at Cell Design Labs, Inc. (CDL). Prior to joining CDL, he was Vice President of Synthetic Immunology at Intrexon Corporation and was Vice President of Immune Mediated Therapy in the Oncology Innovative Medicines group at Medimmune. At Medimmune, Dr. Emtage designed and implemented a comprehensive immune therapy cancer strategy. He has over sixteen years of biologics development experience in the fields of oncology, autoimmunity, infectious diseases, and inflammation. Dr. Emtage holds a B.S. and M.S. in Molecular Biology and Genetics from the University of Guelph and received his Ph.D. in Molecular Virology, Immunology and Inflammation at McMaster University. At the beginning of his career, he also was a post-doctoral fellow at the National Institutes of Health and held roles at Aventis Pasteur and Harvard Medical School.

 

Dr. Aaron Foster

VP of Translational Research
Bellicum Pharmaceuticals

Dr. Aaron Foster

VP of Translational Research
Bellicum Pharmaceuticals

Dr. Aaron Foster

VP of Translational Research
Bellicum Pharmaceuticals
 

Dr. Matthew Spear

Chief Medical Officer
Poseida Therapeutics

Dr. Matthew Spear

Chief Medical Officer
Poseida Therapeutics

Dr. Matthew Spear

Chief Medical Officer
Poseida Therapeutics
 

Neehar Bhatia

Director, Process Development and Manufacturing
Stanford Laboratory for Cell and Gene Medicine

Neehar Bhatia, Ph.D. is Associate Director of Process Development and Manufacturing at Laboratory of Cell and Gene Medicine (LCGM), Stanford University. Dr. Bhatia received a Ph.D. in Biochemistry from the Central Drug Research Institute, India. Dr. Bhatia is responsible for development and manufacturing of cGMP compliant cell and gene therapy products at LCGM. Dr. Bhatia oversees manufacturing for multiple projects such as CD19/CD22 bi-specific CAR-T and other T cell based therapies, CD34 HSPC transplant and manufacturing of AAV6 for gene correction in HSPC. Dr.

Neehar Bhatia

Director, Process Development and Manufacturing
Stanford Laboratory for Cell and Gene Medicine

Neehar Bhatia

Director, Process Development and Manufacturing
Stanford Laboratory for Cell and Gene Medicine

Neehar Bhatia, Ph.D. is Associate Director of Process Development and Manufacturing at Laboratory of Cell and Gene Medicine (LCGM), Stanford University. Dr. Bhatia received a Ph.D. in Biochemistry from the Central Drug Research Institute, India. Dr. Bhatia is responsible for development and manufacturing of cGMP compliant cell and gene therapy products at LCGM. Dr. Bhatia oversees manufacturing for multiple projects such as CD19/CD22 bi-specific CAR-T and other T cell based therapies, CD34 HSPC transplant and manufacturing of AAV6 for gene correction in HSPC. Dr. Bhatia has lead multiple projects which include banking  of ESCs, iPSCs, MSCs and iPSC derived differentiated cells, development of GMP process for translational projects and manufacturing cell therapies for Phase I/II clinical trials. Dr. Bhatia has also lead efforts in quest for serum-free chemically defined culture medium for MSCs and development of platform technology for AAV production. Dr. Bhatia’s focus is on development of cGMP compliant manufacturing process for “bench to bedside” cell and gene therapies.

 

Steven Feldman

Director, Manufacturing and Development
Stanford Laboratory for Cell and Gene Medicine

Dr. Steven A. Feldman was a Staff Scientist and Director of the Vector Production Facility at Surgery Branch, NCI for the past twelve years.  Dr. Feldman’s group was responsible for the development, characterization, and manufacturing of the viral vectors used in gene therapy clinical trials at the Surgery Branch.  Recently, Dr. Feldman joined the Stanford Center for Cancer Cell Therapy as Director of Manufacturing and Process Science where he will take a lead role in the development and manufacture of viral vectors and novel cell therapies for the treatment of cancer.

Steven Feldman

Director, Manufacturing and Development
Stanford Laboratory for Cell and Gene Medicine

Steven Feldman

Director, Manufacturing and Development
Stanford Laboratory for Cell and Gene Medicine

Dr. Steven A. Feldman was a Staff Scientist and Director of the Vector Production Facility at Surgery Branch, NCI for the past twelve years.  Dr. Feldman’s group was responsible for the development, characterization, and manufacturing of the viral vectors used in gene therapy clinical trials at the Surgery Branch.  Recently, Dr. Feldman joined the Stanford Center for Cancer Cell Therapy as Director of Manufacturing and Process Science where he will take a lead role in the development and manufacture of viral vectors and novel cell therapies for the treatment of cancer.

 

Bob Valamehr, PhD MBA,

Vice President, Cancer Immunotherapy
Fate Therapeutics Inc

Bob Valamehr, PhD MBA,

Vice President, Cancer Immunotherapy
Fate Therapeutics Inc

Bob Valamehr, PhD MBA,

Vice President, Cancer Immunotherapy
Fate Therapeutics Inc
 

Paul Lammers

President & CEO
Triumvira Immunologics

Paul Lammers

President & CEO
Triumvira Immunologics

Paul Lammers

President & CEO
Triumvira Immunologics
 

Professor David Miklos

Professor
Stanford University Medical Center

Professor David Miklos

Professor
Stanford University Medical Center

Professor David Miklos

Professor
Stanford University Medical Center
 

Dr. Leonard Lichtenfeld

Acting Chief Medical Officer
American Cancer Society

Dr. Leonard Lichtenfeld

Acting Chief Medical Officer
American Cancer Society

Dr. Leonard Lichtenfeld

Acting Chief Medical Officer
American Cancer Society
 

Kim Nguyen, PhD

Director, CMC
Precision Biosciences

Kim is a part of the Cell Therapy team at Precision Biosciences focused on the process development, analytics, and manufacturing of allogeneic CAR-T cell products. Before joining Precision Biosciences, she served as Principal Scientist and Senior Manager for Strategic Initiatives at Terumo BCT. Kim received her AB from Princeton University and her Ph.D. from Columbia University, both in Chemistry. She enjoys cooking Vietnamese food, reading, and adventures with her adorable Jack Russell terrier, Grover, aka Mr. Shambles.

Kim Nguyen, PhD

Director, CMC
Precision Biosciences

Kim Nguyen, PhD

Director, CMC
Precision Biosciences

Kim is a part of the Cell Therapy team at Precision Biosciences focused on the process development, analytics, and manufacturing of allogeneic CAR-T cell products. Before joining Precision Biosciences, she served as Principal Scientist and Senior Manager for Strategic Initiatives at Terumo BCT. Kim received her AB from Princeton University and her Ph.D. from Columbia University, both in Chemistry. She enjoys cooking Vietnamese food, reading, and adventures with her adorable Jack Russell terrier, Grover, aka Mr. Shambles.

 

Donna Rill

Chief Technology Officer
Triumvira Immunologics

Donna Rill

Chief Technology Officer
Triumvira Immunologics

Donna Rill

Chief Technology Officer
Triumvira Immunologics
 

John T. Elliott

Cell Systems Science Group Leader
National Institute of Standards and Technology

John T. Elliott

Cell Systems Science Group Leader
National Institute of Standards and Technology

John T. Elliott

Cell Systems Science Group Leader
National Institute of Standards and Technology
 

Ali Mohamed

VP CMC
Immatics Biotechnologies

Ali Mohamed

VP CMC
Immatics Biotechnologies

Ali Mohamed

VP CMC
Immatics Biotechnologies
 

Andrew Spiegal

Executive Director
Global Colon Cancer Association

Andrew Spiegal

Executive Director
Global Colon Cancer Association

Andrew Spiegal

Executive Director
Global Colon Cancer Association
 

Fabio Fachin

Head, Cell Therapy Engineering & Automation
Takeda

Fabio Fachin

Head, Cell Therapy Engineering & Automation
Takeda

Fabio Fachin

Head, Cell Therapy Engineering & Automation
Takeda
 

Peggy Sotiropoulou

Director, Research and Development
Celyad

Peggy Sotiropoulou

Director, Research and Development
Celyad

Peggy Sotiropoulou

Director, Research and Development
Celyad
 

Pascal Touchon

CEO
Atara Biotherapeutics

Pascal Touchon

CEO
Atara Biotherapeutics

Pascal Touchon

CEO
Atara Biotherapeutics
 

Paul Rennert

Chief Scientific Officer
Aleta

Paul Rennert

Chief Scientific Officer
Aleta

Paul Rennert

Chief Scientific Officer
Aleta
 

Steve Shamah

Head of Research
Obsidian Therapeutics

Steve Shamah

Head of Research
Obsidian Therapeutics

Steve Shamah

Head of Research
Obsidian Therapeutics
 

Christine E Brown

Professor
City of Hope

Christine E Brown

Professor
City of Hope

Christine E Brown

Professor
City of Hope
 

Bryan Choi, M.D.

Department of Neurosurgery
Massachusetts General Hospital

Bryan Choi, M.D.

Department of Neurosurgery
Massachusetts General Hospital

Bryan Choi, M.D.

Department of Neurosurgery
Massachusetts General Hospital
 

Ran Reshef

Associate Professor
Columbia University

Ran Reshef

Associate Professor
Columbia University

Ran Reshef

Associate Professor
Columbia University
 

Haro Hartounian

Senior Executive Director
BioPharma Innovation

Haro Hartounian

Senior Executive Director
BioPharma Innovation

Haro Hartounian

Senior Executive Director
BioPharma Innovation
 

Jeffrey Miller

Professor
University of Minnesota

Jeffrey Miller

Professor
University of Minnesota

Jeffrey Miller

Professor
University of Minnesota
 

James Trager

Chief Scientific Officer
Nkarta

James Trager

Chief Scientific Officer
Nkarta

James Trager

Chief Scientific Officer
Nkarta
 

Alex Franzusoff

CEO
PACT Pharma

Alex Franzusoff

CEO
PACT Pharma

Alex Franzusoff

CEO
PACT Pharma
 

Roman Yelensky

CTO
Gritstone Oncology

Roman Yelensky

CTO
Gritstone Oncology

Roman Yelensky

CTO
Gritstone Oncology
 

Caron Jacobson

Medical Director
Dana-Faber Cancer Institute

Caron Jacobson

Medical Director
Dana-Faber Cancer Institute

Caron Jacobson

Medical Director
Dana-Faber Cancer Institute
 

Marcelo Pasquini

Senior Scientific Director of Clinical Trials Support
CIBMTR

Marcelo Pasquini

Senior Scientific Director of Clinical Trials Support
CIBMTR

Marcelo Pasquini

Senior Scientific Director of Clinical Trials Support
CIBMTR

Platinum Partners

Event Partners

Become a Sponsor

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Wednesday, November 20, 2019 to Friday, January 24, 2020
ACADEMIC/CLINICIAN SUPER EARLY BIRD
$899
Super early bird ends 24 January 2020
Must be a full time academic or healthcare professional
2 day conference pass
Networking opportunities
Refreshments, breakfast & lunch
To increase your brand presence, contact Nathan Edwards [email protected]
Wednesday, November 20, 2019 to Friday, January 24, 2020
SMALL BIOTECH SUPER EARLY BIRD
$999
Super early bird ends 24 January 2020
Revenue under $7m
2 day conference pass
Networking opportunities
Refreshments, breakfast & lunch
To increase your brand presence, contact Nathan Edwards, [email protected]
Wednesday, November 20, 2019 to Friday, January 24, 2020
INDUSTRY SUPER EARLY BIRD
$1,499
Super early bird ends 24 January 2020
Biotechs over $7m revenue, Pharmaceutical companies
2 day conference pass
Networking opportunities
Refreshments, breakfast & lunch
To increase your brand presence, contact Nathan Edwards, [email protected]
Wednesday, November 20, 2019 to Friday, January 24, 2020
SERVICE PROVIDER/VENDOR SUPER EARLY BIRD
$1,899
Super early bird ends 24 January 2020
2 day conference pass
Networking opportunities
Refreshments, breakfast & lunch
To increase your brand presence, contact Nathan Edwards, [email protected]
Consultants & Investor Rate
Preparing registration...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Other events you might be interested in:

CAR-T Congress EU 2020

Vein-to-Vein EU